PATENT CLAIM ANALYSIS

Application Number: 15759305
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Claim (Index 2):
The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to  claim 1 , wherein the antisense oligomer is (c) or (d) shown below:\n (c) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (c-1) to (c-6) shown below:\n (c-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions \u221210 to 45 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (c-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (c-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (c-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 166 to 210 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; \n (c-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 204 to 233 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; and \n (c-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5\u2032-terminal end of exon 2 in the human myostatin gene; or \n (d) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (d-1) to (d-7) shown below:\n (d-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions \u221210 to 65 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (d-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (d-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (d-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 151 to 210 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (d-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 196 to 233 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; \n (d-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 266 to 295 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene; and \n (d-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5\u2032-terminal end of exon 2 in the mouse myostatin gene.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15759267', '15314535', '14368307', '15122435', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8129444542106458
- 35 USC 102 Novelty (BERT): 0.5659190862100714
- Combined Prediction Score: 0.7882419174105884
- Mean Citation Score: 427.308318
- Max Citation Score: 475.8151
- Similarity Product: 366.7680892814636

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test